The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation. In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.10.018 | DOI Listing |
Publication Analysis
Top Keywords
perioperative immunotherapy
8
urothelial carcinoma
8
path forward
8
immunotherapy urothelial
4
carcinoma ambassador
4
ambassador charts
4
charts path
4
forward ambassador
4
ambassador trial
4
trial revealed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!